Literature DB >> 24111611

Genetics on a WHIM.

Omar Al Ustwani1, Razelle Kurzrock, Meir Wetzler.   

Abstract

We initially described the WHIM syndrome based on the combination of Warts, Hypogammaglobulinaemia, Infections and Myelokathexis (neutrophil retention in the bone marrow). Translational research led to the discovery that this rare immunodeficiency disease is caused by a heterozygous mutation in the CXCR4 gene. Recently, Plerixafor has been suggested as a treatment for WHIM syndrome due to its efficacy as a CXCR4 antagonist, closing the translational research loop. In this review, we will focus on the clinical manifestations, pathophysiology, diagnosis and possible therapies for this rare entity.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  CXCR4; WHIM; myelokathexis; neutropenia; plerixafor

Mesh:

Substances:

Year:  2013        PMID: 24111611      PMCID: PMC3961560          DOI: 10.1111/bjh.12574

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  76 in total

Review 1.  Regulation of CXCR4 signaling.

Authors:  John M Busillo; Jeffrey L Benovic
Journal:  Biochim Biophys Acta       Date:  2006-11-10

2.  Successful umbilical cord blood stem cell transplantation in a child with WHIM syndrome.

Authors:  Gergely Kriván; Melinda Erdos; Krisztián Kállay; Gábor Benyó; Agnes Tóth; János Sinkó; Vera Goda; Beáta Tóth; László Maródi
Journal:  Eur J Haematol       Date:  2009-10-29       Impact factor: 2.997

3.  Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice.

Authors:  Q Ma; D Jones; P R Borghesani; R A Segal; T Nagasawa; T Kishimoto; R T Bronson; T A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

Review 4.  Cloning and characterization of human chemokine receptors.

Authors:  C A Power; T N Wells
Journal:  Trends Pharmacol Sci       Date:  1996-06       Impact factor: 14.819

5.  Live imaging of neutrophil motility in a zebrafish model of WHIM syndrome.

Authors:  Kevin B Walters; Julie M Green; Jill C Surfus; Sa Kan Yoo; Anna Huttenlocher
Journal:  Blood       Date:  2010-06-30       Impact factor: 22.113

6.  B-cell lymphoma in a patient with WHIM syndrome.

Authors:  K M Chae; J O Ertle; M D Tharp
Journal:  J Am Acad Dermatol       Date:  2001-01       Impact factor: 11.527

7.  Clinical and genetic diagnosis of warts, hypogammaglobulinemia, infections, and myelokathexis syndrome in 10 patients.

Authors:  Laura Tassone; Lucia D Notarangelo; Vanessa Bonomi; Gianfranco Savoldi; Alberto Sensi; Annarosa Soresina; C I Edvard Smith; Fulvio Porta; Alessandro Plebani; Luigi D Notarangelo; Raffaele Badolato
Journal:  J Allergy Clin Immunol       Date:  2009-03-24       Impact factor: 10.793

8.  Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization.

Authors:  M J Dugan; R T Maziarz; W I Bensinger; A Nademanee; J Liesveld; K Badel; C Dehner; C Gibney; G Bridger; G Calandra
Journal:  Bone Marrow Transplant       Date:  2009-06-01       Impact factor: 5.483

9.  The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract.

Authors:  K Tachibana; S Hirota; H Iizasa; H Yoshida; K Kawabata; Y Kataoka; Y Kitamura; K Matsushima; N Yoshida; S Nishikawa; T Kishimoto; T Nagasawa
Journal:  Nature       Date:  1998-06-11       Impact factor: 49.962

10.  Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.

Authors:  John F DiPersio; Ivana N Micallef; Patrick J Stiff; Brian J Bolwell; Richard T Maziarz; Eric Jacobsen; Auayporn Nademanee; John McCarty; Gary Bridger; Gary Calandra
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

View more
  13 in total

1.  Heterologous regulation of CXCR4 lysosomal trafficking.

Authors:  Adriana Caballero; Sarah A Mahn; Mudassir S Ali; M Rose Rogers; Adriano Marchese
Journal:  J Biol Chem       Date:  2019-04-01       Impact factor: 5.157

2.  Chromothriptic cure of WHIM syndrome.

Authors:  David H McDermott; Ji-Liang Gao; Qian Liu; Marie Siwicki; Craig Martens; Paejonette Jacobs; Daniel Velez; Erin Yim; Christine R Bryke; Nancy Hsu; Zunyan Dai; Martha M Marquesen; Elina Stregevsky; Nana Kwatemaa; Narda Theobald; Debra A Long Priel; Stefania Pittaluga; Mark A Raffeld; Katherine R Calvo; Irina Maric; Ronan Desmond; Kevin L Holmes; Douglas B Kuhns; Karl Balabanian; Françoise Bachelerie; Stephen F Porcella; Harry L Malech; Philip M Murphy
Journal:  Cell       Date:  2015-02-05       Impact factor: 41.582

3.  WHIM Syndrome Caused by Waldenström's Macroglobulinemia-Associated Mutation CXCR4 (L329fs).

Authors:  Qian Liu; Catherina Pan; Lizbeeth Lopez; Jiliang Gao; Daniel Velez; Sandra Anaya-O'Brien; Jean Ulrick; Patricia Littel; John S Corns; Donald T Ellenburg; Harry L Malech; Philip M Murphy; David H McDermott
Journal:  J Clin Immunol       Date:  2016-04-08       Impact factor: 8.317

Review 4.  Multisystem multitasking by CXCL12 and its receptors CXCR4 and ACKR3.

Authors:  Philip M Murphy; Lauren Heusinkveld
Journal:  Cytokine       Date:  2018-02-15       Impact factor: 3.861

Review 5.  New monogenic disorders identify more pathways to neutropenia: from the clinic to next-generation sequencing.

Authors:  Seth J Corey; Usua Oyarbide
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 6.  WHIM Syndrome: from Pathogenesis Towards Personalized Medicine and Cure.

Authors:  Lauren E Heusinkveld; Shamik Majumdar; Ji-Liang Gao; David H McDermott; Philip M Murphy
Journal:  J Clin Immunol       Date:  2019-07-16       Impact factor: 8.317

Review 7.  Primary immunodeficiency update: Part II. Syndromes associated with mucocutaneous candidiasis and noninfectious cutaneous manifestations.

Authors:  Dominique C Pichard; Alexandra F Freeman; Edward W Cowen
Journal:  J Am Acad Dermatol       Date:  2015-09       Impact factor: 11.527

Review 8.  Neutrophils as emerging therapeutic targets.

Authors:  Tamás Németh; Markus Sperandio; Attila Mócsai
Journal:  Nat Rev Drug Discov       Date:  2020-01-22       Impact factor: 84.694

9.  Human polyomaviruses and incidence of cutaneous squamous cell carcinoma in the New Hampshire skin cancer study.

Authors:  Anala Gossai; Tim Waterboer; Anne G Hoen; Shohreh F Farzan; Heather H Nelson; Angelika Michel; Martina Willhauck-Fleckenstein; Brock C Christensen; Ann E Perry; Michael Pawlita; Margaret R Karagas
Journal:  Cancer Med       Date:  2016-02-21       Impact factor: 4.452

10.  Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.

Authors:  David C Dale; Emily Dick; Merideth Kelley; Vahagn Makaryan; Jim Connelly; Audrey Anna Bolyard
Journal:  Curr Opin Hematol       Date:  2020-01       Impact factor: 3.218

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.